Evidence map›Paper›PMID 19694534›Full record

ArticleHuman gene therapy2009

Molecularly evolved thymidylate synthase inhibits 5-fluorodeoxyuridine toxicity in human hematopoietic cells.

Jason H Bielas, Michael W Schmitt, Amalia Icreverzi, Nolan G Ericson, Lawrence A Loeb

Open access · greenAbstract read
In one paragraph

Article in Human gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jason H BielasMolecular Diagnostics Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. jbielas@fhcrc.org
Michael W Schmitt
Amalia Icreverzi
Nolan G Ericson
Lawrence A Loeb
Fred Hutch Cancer Center · US

Funding

University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
CREATING MUTANT ENZYMES FOR GENE THERAPY OF CANCERR01CA078885 · NCI · UNIVERSITY OF WASHINGTON · PI LOEB, LAWRENCE A · 1998 to 2007
$3.7M
Fidelity of DNA SynthesisR01CA102029 · NCI · UNIVERSITY OF WASHINGTON · PI LOEB, LAWRENCE A · 2003 to 2012
$3.3M
Mitochondrial DNA Replication FidelityF30AG030314 · NIA · UNIVERSITY OF WASHINGTON · PI SCHMITT, MICHAEL WILLIAM · 2007 to 2010
$132k
CIHRNCI NIH HHS CA102029NCI NIH HHS CA78885NCI NIH HHS R01 CA078885NCI NIH HHS R01 CA102029NIA NIH HHS AG030314NIGMS NIH HHS GM007266
6 · The paper itself

Abstract

Thymidylate synthase (TS) inhibitors, such as 5-fluorouracil (5-FU) and 5-fluorodeoxyuridine (5-FUdR), are amongst the most frequently used chemotherapeutic drugs available, although their efficacy is often limited by myelotoxicity. An emerging strategy for overcoming bone marrow toxicity involves ex vivo genetic transfer of drug resistance to autologous hematopoietic progenitor cells, followed by reimplantation of the transfected cells before chemotherapy. Here we establish that expression of mutant TS genes, selected from millions of engineered variants, renders human hematopoietic cells resistant to 5-FUdR, and identify the most efficacious variant for gene therapeutic rescue of drug-induced myelosuppression.

Indexed as

Transduction, GeneticAmino Acid SubstitutionAntimetabolites, AntineoplasticDrug ResistanceFloxuridineGene ExpressionGenetic TherapyHematopoietic Stem CellsHumansProtein ConformationSuppression, GeneticThymidylate SynthaseAntimetabolites, AntineoplasticFloxuridineThymidylate Synthase

Identifiers

PMID19694534
PMCPMC2829455
OpenAlexW2007252144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.